Globus Medical Inc. Class A Common Stock vs Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares) — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares) trades at $9.45 (market cap $114.26B). The key difference: Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares) is far larger — about 11.1× Globus Medical Inc. Class A Common Stock's market cap, and Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares) pays a 1.73% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares) for 3 Days on average.
| GMED | ITUB | |
|---|---|---|
Market Cap | $10.25B | $114.26B |
Volume | 1,108,124 | 41,905,072 |
Sector | Health | Financials |
52-Week High | $96.82 | $10.16 |
52-Week Low | $58.33 | $6.86 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $9.76B | $1.34T |
Dividend Yield | — | 1.73% |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
ITUB trades at $9.89, down 1.69% today, following recent profit-taking after reaching 52-week highs. The stock shows bullish technical momentum with strong moving average signals, though RSI indicates overbought conditions. Fundamentally, the bank maintains robust profitability with 27.65% net margin and 21.97% ROE, though recent quarters have seen earnings misses. The company recently received preliminary US bank charter approval, expanding its wealth management services for Latin American clients.
Outlook remains cautiously optimistic with analyst consensus at Buy (46%) and price target of $9.80. Key opportunities include US expansion and strong Brazilian market position, while risks include Brazil's high risk-free rate, competitive pressures, and earnings consistency concerns. The stock trades near fair value with P/E of 11.75 and P/B of 2.5.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →Itaú Unibanco is a Brazilian financial services company providing banking, credit, insurance, and investment products. It serves individual, business, and corporate clients.
Read more on ITUB →